New drug shows promise for boosting growth in kids with dwarfism
NCT ID NCT06164951
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a daily oral drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate compared to a placebo. The trial is now complete, and results will show whether this drug can become a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Infigratinib (a daily oral drug)
What this could lead to
If it works, this could become a new treatment to help children with achondroplasia grow taller.
What could go wrong
This is a completed Phase 3 trial, but results are not yet public. The drug may not work better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
QED Investigative Site
San Francisco, California, 94609, United States
-
QED Investigative Site
Aurora, Colorado, 80045, United States
-
QED Investigative Site
Baltimore, Maryland, 21287, United States
-
QED Investigative Site
Columbia, Missouri, 65212, United States
-
QED Investigative Site
Cincinnati, Ohio, 45229, United States
-
QED Investigative Site
Nashville, Tennessee, 37232, United States
-
QED Investigative Site
Madison, Wisconsin, 53792, United States
-
QED Investigative Site
Buenos Aires, Buenos Aires F.D., C1245AAM, Argentina
-
QED Investigative Site
Parkville, Victoria, 3052, Australia
-
QED Investigative Site
Edmonton, Alberta, T6G 2B7, Canada
-
QED Investigative Site
London, Ontario, N6A 5W9, Canada
-
QED Investigative Site
Ottawa, Ontario, K1H 8L1, Canada
-
QED Investigative Site
Montreal, Quebec, H3T 1C5, Canada
-
QED Investigative Site
Bron, 69677, France
-
QED Investigative Site
Paris, 75015, France
-
QED Investigative Site
Toulouse, 31059, France
-
QED Investigative Site
Rome, 00168, Italy
-
QED Investigative Site
Bergen, 5009, Norway
-
QED Investigative Site
Oslo, 0372, Norway
-
QED Investigative Site
Singapore, 229899, Singapore
-
QED Investigative Site
Málaga, 29010, Spain
-
QED Investigative Site
Vitoria-Gasteiz, 01008, Spain
-
QED Investigative Site
Bristol, BS2 8BJ, United Kingdom
-
QED Investigative Site
Glasgow, G51 4TF, United Kingdom
-
QED Investigative Site
London, SE1 7EH, United Kingdom
-
QED Investigative Site
Manchester, M13 9WL, United Kingdom
-
QED Investigative Site
Sheffield, S10 2TH, United Kingdom